Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04460898 · ClinicalTrials.gov registry record
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 195
- Enrollment target
NCT04460898 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 195 participants.
The verdict
NCT04460898 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 195 participants
- Enrollment target
Study Summary
This is a retrospective, observational study that will document treatment patterns and clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received Palbociclib plus Letrozole as initial endocrine-based therapy in US community oncology network settings.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2019-06-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04460898
The ClinicalTrials.gov registry entry for NCT04460898 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04460898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04460898 about?
NCT04460898 is a clinical study titled "RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.". This is a retrospective, observational study that will document treatment patterns and clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received Palbociclib plus Letrozole as initial endocrine-based therapy in US community oncology network settings.
What is the current status of trial NCT04460898?
This trial is currently completed. The enrollment target is 195 participants. The study started on 2019-01-04. Estimated completion is 2019-06-24.
Who is sponsoring clinical trial NCT04460898?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.